Bilge Muge, Akilli Isil Kibar, Karaayvaz Ekrem Bilal, Yesilova Aylia, Kart Yasar Kadriye
Department of Internal Medicine, Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Darulaceze Street, No: 27 Sisli, 34384, Istanbul, Turkey.
Department of Pulmonary Disease, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Halaskargazi Street, 34371, Istanbul, Turkey.
Infect Agent Cancer. 2021 Sep 15;16(1):60. doi: 10.1186/s13027-021-00400-4.
We evaluated several biological indicators based on inflammation and/or nutritional status, such as systemic immune-inflammation index (SII), early warning score (ANDC) and prognostic nutritional index (PNI) in hospitalized COVID-19 patients with and without malignancies for a prognostic significance.
This is a retrospective and observational study on 186 patients with SARS-CoV-2, who were diagnosed with COVID-19 by real-time PCR testing and hospitalized due to COVID-19 pneumonia. 75 patients had various malignancies, and the rest (111), having a similar age and comorbidity profile based on propensity score matching, had no malignancy.
None of the measures as neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, monocyte to lymphocyte ratio, SII, PNI or ANDC was found to be significantly different between two groups. Odds ratio for the mortality, OR 2.39 (%95 CI 1.80-3.16) was found to be significantly higher for the malignancy group, even though the duration of hospitalization was statistically similar for both groups. PNI was found to be significantly lower for deceased patients compared with survivors in the malignancy group. Contrarily, ANDC was found to be significantly higher for deceased patients in the malignancy group.
PNI and ANDC have independent predictive power on determining the in-hospital death in COVID-19 malignancy cases. It is suggested that ANDC seems to be a more sensitive score than SII in COVID-19 cases with malignancies.
我们评估了几种基于炎症和/或营养状况的生物学指标，如全身免疫炎症指数（SII）、预警评分（ANDC）和预后营养指数（PNI），以探讨其在合并或未合并恶性肿瘤的住院COVID-19患者中的预后意义。
这是一项对186例SARS-CoV-2患者的回顾性观察研究，这些患者通过实时PCR检测确诊为COVID-19，并因COVID-19肺炎住院。75例患者患有各种恶性肿瘤，其余111例根据倾向评分匹配，年龄和合并症情况相似，未患恶性肿瘤。
两组之间的中性粒细胞与淋巴细胞比率、血小板与淋巴细胞比率、单核细胞与淋巴细胞比率、SII、PNI或ANDC等指标均无显著差异。恶性肿瘤组的死亡率比值比（OR）为2.39（95%CI 1.80-3.16），显著高于非恶性肿瘤组，尽管两组的住院时间在统计学上相似。在恶性肿瘤组中，死亡患者的PNI显著低于存活患者。相反，恶性肿瘤组中死亡患者的ANDC显著高于存活患者。
PNI和ANDC在确定COVID-19合并恶性肿瘤患者的院内死亡方面具有独立的预测能力。在合并恶性肿瘤的COVID-19病例中，ANDC似乎比SII更敏感。
